Explore

Reuters Reuters
AstraZeneca holds talks with Bristol Myers Squibb on $400 billion megadeal, FT reports

AstraZeneca holds talks with Bristol Myers Squibb on $400 billion megadeal, FT reports

Aug 2 (Reuters) - UK drugmaker AstraZeneca has been exploring a deal to combine with U.S. rival Bristol Myers Squibb, the Financial Times reported on Sunday, citing people familiar with the matter.
Trendline Trendline
AstraZeneca Engages in Talks with Bristol Myers Squibb for Potential $400 Billion Merger

AstraZeneca Engages in Talks with Bristol Myers Squibb for Potential $400 Billion Merger

AstraZeneca Engages in Talks with Bristol Myers Squibb for Potential $400 Billion Merger
Trendline Trendline
FDA Advisory Committee Supports Replimune's Melanoma Drug Amid Data Concerns

FDA Advisory Committee Supports Replimune's Melanoma Drug Amid Data Concerns

FDA Advisory Committee Supports Replimune's Melanoma Drug Amid Data Concerns
TheStreet TheStreet
Novo Nordisk shares in hot water after disappointing trial

Novo Nordisk shares in hot water after disappointing trial

Investors who had hopes that Novo Nordisk (NVO) could succeed outside of weight-loss drugs were disappointed on Friday, July 31. The Danish drugmaker said its experimental heart drug Ziltivekimab failed the main goal of a large late-stage trial, and the stock fell fast. Novo has spent 2026 trying ...
Trendline Trendline
Novo Nordisk Faces Setback as Heart Drug Trial Fails to Meet Key Endpoint

Novo Nordisk Faces Setback as Heart Drug Trial Fails to Meet Key Endpoint

Novo Nordisk Faces Setback as Heart Drug Trial Fails to Meet Key Endpoint
Trendline Trendline
AstraZeneca's Strategic Partnerships and Product Portfolio Drive Growth

AstraZeneca's Strategic Partnerships and Product Portfolio Drive Growth

AstraZeneca's Strategic Partnerships and Product Portfolio Drive Growth
Trendline Trendline
Moderna Reports Q2 2026 Revenue Decline Amid Lower U.S. COVID Vaccine Sales

Moderna Reports Q2 2026 Revenue Decline Amid Lower U.S. COVID Vaccine Sales

Moderna Reports Q2 2026 Revenue Decline Amid Lower U.S. COVID Vaccine Sales
Trendline Trendline
Bristol Myers Squibb Raises 2026 Revenue Forecast Following Strong Q2 Earnings

Bristol Myers Squibb Raises 2026 Revenue Forecast Following Strong Q2 Earnings

Bristol Myers Squibb Raises 2026 Revenue Forecast Following Strong Q2 Earnings
Trendline Trendline
Novo Nordisk Faces Setback as Heart Drug Trial Fails, Impacting Stock Value

Novo Nordisk Faces Setback as Heart Drug Trial Fails, Impacting Stock Value

Novo Nordisk Faces Setback as Heart Drug Trial Fails, Impacting Stock Value
Reuters Reuters
Musk dismisses report of Tesla's potential China business sale

Musk dismisses report of Tesla's potential China business sale

July 30 (Reuters) - Elon Musk dismissed as "fake news" a report that executives at his electric vehicle company Tesla have been told to prepare for a separation of its China business ahead of a potential merger with his space exploration firm SpaceX.
Trendline Trendline
Kaigene and Taisho Pharmaceutical Partner for Autoimmune Drug Development in Japan

Kaigene and Taisho Pharmaceutical Partner for Autoimmune Drug Development in Japan

Kaigene and Taisho Pharmaceutical Partner for Autoimmune Drug Development in Japan
Trendline Trendline
Elon Musk Denies Report of Tesla's Potential China Business Sale

Elon Musk Denies Report of Tesla's Potential China Business Sale

Elon Musk Denies Report of Tesla's Potential China Business Sale